Core Laboratories (CLB) posts Q3 2025 results, $0.01 dividend

Core Laboratories Inc. (CLB) reported that it issued a press release announcing its financial results for the third quarter of 2025.

Rhea-AI Filing Summary

Core Laboratories Inc. (CLB) reported that it issued a press release announcing its financial results for the third quarter of 2025. The company also declared a quarterly cash dividend of $0.01 per share, payable to shareholders of record on November 3, 2025 and payable on November 24, 2025.

The press release is furnished as Exhibit 99.1. The information is being furnished under Items 2.02 and 7.01 and is not deemed filed for liability purposes.

Insights

Equity markets analyst

Routine 8-K: results furnished and $0.01 dividend declared.

Core Laboratories furnished third-quarter 2025 results via press release and declared a quarterly dividend of $0.01 per share. Furnished status under Items 2.02 and 7.01 means it is not deemed filed for Section 18 liability.

The dividend record date is November 3, 2025 and payment date is November 24, 2025. Absent detailed metrics in this excerpt, the disclosure reads as administrative and consistent with routine communications.

8-K Event Classification

2 items: 2.02, 7.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Core Laboratories (CLB) announce in this 8-K?

The company furnished a press release with Q3 2025 financial results and declared a $0.01 per share quarterly cash dividend.

What is the amount of CLB's quarterly dividend?

Core Laboratories declared a quarterly cash dividend of $0.01 per share.

What are the record and payment dates for CLB's dividend?

Shareholders of record on November 3, 2025 will be paid on November 24, 2025.

Where can I find the detailed Q3 2025 results for CLB?

The full text of the press release with results is furnished as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

The items and Exhibit 99.1 are furnished and not deemed filed for Section 18 of the Exchange Act.

Which items of the 8-K are referenced?

Item 2.02 (Results of Operations) and Item 7.01 (Reg FD Disclosure).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 04:15 PM Learn about SEC filing dates

0001958086false00019580862025-10-222025-10-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2025

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41695	98-1164194
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
6316 Windfern Road
Houston, TX		77040
(Address of principal executive offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (713) 328-2673

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock (par value $0.01)		CLB		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 22, 2025, Core Laboratories Inc. issued a press release announcing its financial results for the third quarter of 2025.

Item 7.01 Regulation FD Disclosure.

On October 22, 2025, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on November 3, 2025 and payable November 24, 2025.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued on October 22, 2025 *

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

* This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Core Laboratories Inc.
Dated: October 22, 2025		By		/s/ Christopher S. Hill
				Christopher S. Hill
				Chief Financial Officer